Rabies Monoclonal Antibody (MCAB)
Classification:
Products in the Pipeline
- Product Description
- Immunogenicity
- Security
- Mad Dog Bite Cases
-
Manufacturing Process
The project is designed to create a "cocktail" combination preparation against rabies virus with broad-spectrum of the neutralizing activity, and is an important product for synergistically preventing rabies after severe exposure in conjunction with rabies vaccines. The product employs fully human sourced monoclonal antibodies to ensure better safety.
Current Progress
In pre-clinical study.
Previous Page
Previous Page
Other Products
Inactivated Japanese Encephalitis Vaccine for Human Use (Vero cell) (IJEV)
SPEEDA-Rabies Vaccine for Human Use (Vero cell) (CPRV)
Rabies Vaccine (Human Diploid Cell) for Human Use, Freeze-dried (HDCV)
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent (QIV)
13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV 13)
Recombinant Human Papillomavirus 15-valent Vaccine (Escherichia. Coli) (HPV 15)
Follow us
Telephone
Marketing Center
International Trade
Medical Consultation
Address
No.1, XinFang Street, Hunnan New District, Shenyang City
123456789
12456789